贝达药业拟港股上市，上半年“增收不增利”

Group 1 - Bidafarma plans to issue overseas listed shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to enhance capital strength and competitiveness [2][5] - The company has previously submitted applications to the Hong Kong Stock Exchange twice in 2021, with the first submission on February 8 and the second on December [6] - The company is currently discussing the details of the issuance with relevant intermediaries, and the issuance is subject to approval from the shareholders' meeting and regulatory authorities [5][6] Group 2 - In the first half of 2025, Bidafarma achieved operating revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but the net profit attributable to shareholders decreased by 37.53% to 140 million yuan, indicating a "revenue increase without profit increase" phenomenon [7] - The company has eight drugs currently on the market, but faces competitive pressures in specific areas, including competition from first and third-generation drugs in the EGFR-TKI market and market challenges in the ALK inhibitor field [8]